FibroGen (FGEN) Misses Q2 EPS by 20c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.90), $0.20 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $44.32 million versus the consensus estimate of $34.73 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Worried the AI trade has gone too far? Evercore likes these 4 stocks